CorMedix (CRMD) FY2025 10-K Risk Factors: 14 New, 10 Dropped

What the changes say

CorMedix turned profitable in 2025 with $163.1 million in net income, reducing its accumulated deficit to $176.6 million.

What changed since the prior 10-K

New

NewRisks Related to the Development and Commercialization of DefenCath
Our revenue and profitability may be adversely affected by DefenCath’s transition from TDAPA to the post-TDAPA add-on adjustment and broader reimbursement dynamics that could have a material adverse impact on our results of operations and business
DefenCath's TDAPA reimbursement will transition to a post-TDAPA add-on adjustment on July 1, 2026, leading to lower CMS reimbursement and reduced net pricing.
NewRisks Related to the Development and Commercialization of our other Products
Because of these risks, our development efforts and those of our licensor and our partners may not result in any future commercially viable products
Development efforts by CorMedix, its licensors, and partners may fail to result in commercially viable products.
NewRisks Related to the Development and Commercialization of our other Products
Infective pathogens might develop resistance to our Products or product candidates, which would decrease the efficacy and commercial viability of that product
Infective pathogens may develop resistance to the company's products and candidates over time through genetic mutation, reducing efficacy.
NewRisks Related to the Development and Commercialization of our other Products
Clinical trials and regulatory approval for our product lines are expensive, time-consuming, and uncertain, and failure or delay in obtaining approval could materially harm our business
Clinical trials and FDA approval processes are expensive, lengthy, and subject to delays or failures from patient enrollment issues, manufacturing constraints, or safety concerns.
NewRisks Related to the Development and Commercialization of our other Products
Off-label marketing or use of our Products or future product candidates may expose us to significant fines, penalties, sanctions, or product liability claims, and our reputation could be harmed
Off-label marketing or promotion of products outside approved labeling could result in government investigations, large fines, consent decrees, or product liability claims.
NewRisks Related to Our Business and Industry
We have pursued and may continue to pursue acquisitions. Acquisitions could be difficult to integrate, divert the attention of key personnel, disrupt our business, dilute stockholder value and impair our financial results
Acquisitions of complementary businesses or technologies may be difficult to integrate, divert management attention, and increase costs.
NewRisks Related to Our Intellectual Property
Our commercial success will depend in part on obtaining further patent protection for our Products, product lines and other technologies and successfully defending any patents that we currently have or will obtain against third-party challenges
The company may fail to obtain, defend, or protect patent rights against competitor challenges or government pricing pressures.
NewRisks Related to Our Intellectual Property
Our business, financial condition, and results of operations could be materially and adversely affected by an adverse outcome in the ongoing litigation
Ongoing litigation, investigations, or legal proceedings could result in significant costs, damages, injunctions, or reputational harm.
NewRisks Related to Dependence on Third Parties
Our ability to pursue the development and commercialization of certain of our Products depends upon the continuation of certain licenses and actions taken by our licensors
The company relies on third-party licenses, including an exclusive license to commercialize REZZAYO in the U.S., which can be terminated for breach or failure to meet milestones.
NewRisks Related to Dependence on Third Parties
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates
Disputes or actions by third-party licensors regarding research programs and product candidates could delay or impair product development.
NewRisks Related to Dependence on Third Parties
The timing of the milestone and royalty payments we are required to make to third parties is uncertain and could adversely affect our cash flows and results of operations
Uncertain timing of milestone and royalty payments owed to third parties could strain cash flows and force unfavorable fundraising.
NewRisks Related to our Common Stock
Our common stock price has fluctuated considerably and is likely to remain volatile, in part due to the limited market for our common stock and you could lose all or a part of your investment
Common stock prices have fluctuated between $5.60 and $17.43 from December 31, 2024, to December 31, 2025, due to market volatility and limited trading volume.
NewRisks Related to our Common Stock
Our business may be adversely affected by tariffs, trade sanctions or similar government actions
NewRisks Related to our Common Stock
We have identified a material weakness in our internal control over financial reporting, which could, if not effectively remediated, result in material misstatements in our financial statements, and a failure to meet our reporting and financial obligations

Dropped

DroppedRisks Related to the Development and Commercialization of our Other Products
Final approval by regulatory authorities of our product lines for commercial use may be delayed, limited or denied, any of which could adversely affect our ability to generate operating revenues
DroppedRisks relating to data privacy could create additional liabilities for us
New legislation may be enacted in other states. The effects on our business of this growing body of privacy and data protection laws are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply
DroppedRisks Related to Our Business and Industry
Healthcare institutions, physicians and patients may not accept and use our products
DroppedRisks Related to Our Business and Industry
If we are unable to effectively recruit, train, retain and equip our sales force, our ability to continue successfully commercialize DefenCath will be harmed
DroppedRisks Related to Our Business and Industry
We may be exposed to liability claims associated with the use of hazardous materials and chemicals
DroppedRisks Related to our Common Stock
Our executive officers and directors may exercise stock options and sell shares of their stock, and these events could adversely affect our stock price
Final approval by regulatory authorities for commercial use may be delayed or denied.
DroppedRisks Related to our Common Stock
The market price of our common stock has fluctuated considerably and may continue to fluctuate significantly in response to a number of factors, some of which are beyond our control
DroppedRisks Related to our Common Stock
A significant number of additional shares of our common stock may be issued at a later date, and their sale could depress the market price of our common stock
DroppedRisks Related to our Common Stock
Additionally, there are 4,756,909 shares of common stock available for grants under the Amended and Restated 2019 Omnibus Stock Plan (adopted on October 13, 2022 and amended on November 21, 2024)
New state data privacy and security legislation could require costly compliance modifications.
DroppedRisks Related to our Common Stock
We are a “smaller reporting company” and we cannot be certain if the reduced reporting requirements applicable to such companies could make our common stock less attractive to investors

Reworded

100% rewrittenRisks Related to Our Intellectual Property
If we and our licensors do not obtain protection for and successfully defend our respective intellectual property rights, competitors may be able to take advantage of our research and development efforts to develop competing products
Removed specific references to the most material patents and consolidated the scope of intellectual property defense.
79% rewrittenRisks Related to Our Financial Position
Although we achieved profitability in 2025, we have a history of operating losses, may incur additional operating losses in the future, and may never achieve sustained profitability
Updated financial figures to reflect net income of $163.1 million for 2025 and an accumulated deficit reduced to $176.6 million.
Was: We have a history of operating losses, may incur additional operating losses in the future and may never achieve sustained profitability
77% rewrittenRisks Related to Regulatory and Legal Compliance Matters
Healthcare policy changes, including reimbursement policies for drugs and medical devices, may have an adverse effect on our business, financial condition and results of operations
Broadened healthcare policy and reimbursement risks from mentioning only DefenCath to encompass all company Products.
64% rewrittenRisks relating to cybersecurity and data privacy could create additional liabilities for us
Clinical trials required for our Products and any future product lines may be expensive, time consuming and their outcome is uncertain
Minor phrasing adjustments regarding the length and uncertainty of clinical trials for Products and future product lines.
Was: Clinical trials required for our product lines, including, but not limited to, new uses or formulations of DefenCath and the required DefenCath PREA study, may be expensive and time-consuming, and their outcome is uncertain
61% rewrittenRisks Related to the Development and Commercialization of our other Products
Successful development and commercialization of our Products and new product lines is uncertain
Expanded development and commercialization risks to explicitly include partners and licensors alongside CorMedix.
Was: Successful development and commercialization of new product lines is uncertain
54% rewrittenRisks Related to Regulatory and Legal Compliance Matters
Our approved Products are, and our pipeline product lines (if approved) will be, subject to extensive post-approval regulation
Specified that post-approval regulatory requirements are FDA-mandated.
Was: Our approved product, DefenCath, is, and our other product lines (if approved) will be, subject to extensive post-approval regulation
47% rewrittenRisks Related to Our Business and Industry
If we lose key management, cannot recruit qualified employees, directors, officers, or other personnel or experience increases in compensation costs, our business may materially suffer
Removed specific executive officer names from the key management dependency risk and added a warning on employee non-compete limits.
Was: If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other personnel or experience increases in compensation costs, our business may materially suffer
44% rewrittenRisks Related to Our Intellectual Property
Intellectual property disputes require us to spend time and money to address such disputes could limit our intellectual property rights and if generic entrants of our Products are approved, it could have a material adverse impact on our results of operations and financial condition
Added a specific warning that generic manufacturers have sought and may seek FDA approval to market generic versions via ANDAs.
Was: Intellectual property disputes could require us to spend time and money to address such disputes and could limit our intellectual property rights
43% rewrittenRisks Related to Dependence on Third Parties
We depend on third-party suppliers and contract manufacturers for the supply and manufacture of our product lines, as well as our APIs, which subjects us to potential cost increases and manufacturing delays that are not within our control
Was: We depend on third-party suppliers and contract manufacturers for the supply and manufacture of DefenCath and our product lines, as well as our APIs, which subjects us to potential cost increases and manufacturing delays that are not within our control
42% rewrittenRisks Related to the Development and Commercialization of DefenCath
We have significant DefenCath customer concentration, with a limited number of customers accounting for a large portion of our revenues
Was: We have significant customer concentration, with a limited number of customers accounting for a large portion of our revenues
29% rewrittenRisks Related to our Common Stock
Our internal control over financial reporting and our disclosure controls and procedures may not prevent all possible errors that could occur
28% rewrittenRisks Related to Our Business and Industry
We may not successfully manage the growth of our Products
Was: We may not successfully manage our growth
24% rewrittenRisks Related to Regulatory and Legal Compliance Matters
Changes in funding for the FDA and other government agencies or future government shutdowns or disruptions could cause delays in the submission and regulatory review of our product lines, which could negatively impact our business or prospects
Was: Changes in funding for the FDA and other government agencies or future government shutdowns or disruptions could cause delays in the submission and regulatory review of marketing applications, including supplements, which could negatively impact our business or prospects

All 32 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Position

01Although we achieved profitability in 2025, we have a history of operating losses, may incur additional operating losses in the future, and may never achieve sustained profitability79% rewritten

Risks Related to the Development and Commercialization of DefenCath

02We are highly dependent on the continued successful commercialization of our lead product, DefenCath
03The continued successful commercialization of DefenCath will depend on maintaining coverage and reimbursement for use of DefenCath from third-party payors
04We have significant DefenCath customer concentration, with a limited number of customers accounting for a large portion of our revenues42% rewritten
05Our revenue and profitability may be adversely affected by DefenCath’s transition from TDAPA to the post-TDAPA add-on adjustment and broader reimbursement dynamics that could have a material adverse impact on our results of operations and businessNew

Risks Related to the Development and Commercialization of our other Products

06Successful development and commercialization of our Products and new product lines is uncertain61% rewritten
07Because of these risks, our development efforts and those of our licensor and our partners may not result in any future commercially viable productsNew
08Infective pathogens might develop resistance to our Products or product candidates, which would decrease the efficacy and commercial viability of that productNew
09Clinical trials and regulatory approval for our product lines are expensive, time-consuming, and uncertain, and failure or delay in obtaining approval could materially harm our businessNew
10Off-label marketing or use of our Products or future product candidates may expose us to significant fines, penalties, sanctions, or product liability claims, and our reputation could be harmedNew

Risks Related to Regulatory and Legal Compliance Matters

11Our approved Products are, and our pipeline product lines (if approved) will be, subject to extensive post-approval regulation54% rewritten
12Healthcare policy changes, including reimbursement policies for drugs and medical devices, may have an adverse effect on our business, financial condition and results of operations77% rewritten
13Changes in funding for the FDA and other government agencies or future government shutdowns or disruptions could cause delays in the submission and regulatory review of our product lines, which could negatively impact our business or prospects24% rewritten

Risks relating to cybersecurity and data privacy could create additional liabilities for us

14Clinical trials required for our Products and any future product lines may be expensive, time consuming and their outcome is uncertain64% rewritten

Risks Related to Our Business and Industry

15We may not successfully manage the growth of our Products28% rewritten
16We have pursued and may continue to pursue acquisitions. Acquisitions could be difficult to integrate, divert the attention of key personnel, disrupt our business, dilute stockholder value and impair our financial resultsNew
17Competition and technological change may make our Products, product lines or indications, less attractive or obsolete
18If we lose key management, cannot recruit qualified employees, directors, officers, or other personnel or experience increases in compensation costs, our business may materially suffer47% rewritten
19We face the risk of product liability claims and the amount of insurance coverage we hold now or in the future may not be adequate to cover all liabilities we might incur

Risks Related to Our Intellectual Property

20If we and our licensors do not obtain protection for and successfully defend our respective intellectual property rights, competitors may be able to take advantage of our research and development efforts to develop competing products100% rewritten
21Our commercial success will depend in part on obtaining further patent protection for our Products, product lines and other technologies and successfully defending any patents that we currently have or will obtain against third-party challengesNew
22Intellectual property disputes require us to spend time and money to address such disputes could limit our intellectual property rights and if generic entrants of our Products are approved, it could have a material adverse impact on our results of operations and financial condition44% rewritten
23Our business, financial condition, and results of operations could be materially and adversely affected by an adverse outcome in the ongoing litigationNew

Risks Related to Dependence on Third Parties

24Our ability to pursue the development and commercialization of certain of our Products depends upon the continuation of certain licenses and actions taken by our licensorsNew
25If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidatesNew
26We depend on third-party suppliers and contract manufacturers for the supply and manufacture of our product lines, as well as our APIs, which subjects us to potential cost increases and manufacturing delays that are not within our control43% rewritten
27We rely on third parties to conduct our clinical trials and pre-clinical studies. If those parties do not successfully carry out their contractual duties or meet expected deadlines, our product lines may not advance in a timely manner or at all
28The timing of the milestone and royalty payments we are required to make to third parties is uncertain and could adversely affect our cash flows and results of operationsNew

Risks Related to our Common Stock

29Our common stock price has fluctuated considerably and is likely to remain volatile, in part due to the limited market for our common stock and you could lose all or a part of your investmentNew
30Our business may be adversely affected by tariffs, trade sanctions or similar government actionsNew
31We have identified a material weakness in our internal control over financial reporting, which could, if not effectively remediated, result in material misstatements in our financial statements, and a failure to meet our reporting and financial obligationsNew
32Our internal control over financial reporting and our disclosure controls and procedures may not prevent all possible errors that could occur29% rewritten

Other CorMedix 10-Ks

FY2024 10-K risk factors
28 risks
Commercialization of DefenCath dominates risk, alongside heavy customer concentration, accumulated deficits, and outsourced manufacturing dependencies.
Filed Mar 25, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.